Tag Archives: BIO EVENT

A Patient at BIO Investor Forum

BIF-2014

“Sir?” The security guard walks to the Partnering desk, slightly confused. “Sir, there’s a man with no badge. He says he’s not registered for the conference. But he says he needs to talk to you.” At BIO events, you can always expect the unexpected. I nod to the guard. “Let him in.” A man. 70s. Stooped; hunched; gnarled. Disheveled. Faded tattoos on his forearms. Yet, a twinkle in his eye and an unexpected motorcycle helmet Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

How to Pitch to Investors

BIO Investor Forum

To help biotechs wow the scores of venture investors attending the BIO Investor Forum conference (San Fran, Oct 7-8), BIO held a “How to Pitch to Investors” web panel featuring David Collier, M.D., Managing Director, CMEA Capital; CEO, Velocity Pharmaceutical Development, Joe Sum, Partner & Analyst, EcoR1 Capital, Adam Cutler, Managing Director, Trout Group, and Tony Tontat, Capital Access Advisors/Boston. The recording of this can’t-miss web panel is here: Here’s a recap of the first Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

The First-Ever BIO Latin America Conference a Major Success

BIO_Latin_America

The first-ever BIO Latin America Conference was a major success and will become an annual must-attend event for those doing business in the region. Rio de Janeiro, SEPTEMBER 2014 – The 2014 BIO Latin America Conference, held on September 9-11, in Rio de Janeiro, brought together the in-depth expertise vital to the growth of the biotech industry in Latin America, and provided the attendees with networking and programming not available at any other regional gathering. Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Gates to contribute $50M for Ebola response

admin-ajax

Bill Gates was on MSNBC’s Morning Joe to discuss the Gates Foundation’s contribution of $50 million to support emergency response to Ebola. Mr. Gates responded to criticism that the U.S. was initially slow to properly address the African crisis. He noted that it would be virtually impossible to respond much quicker to the unprecedented scale of the outbreak. He did call upon other countries to step up and dedicate resources as well. The most recent Read More >

Corporate, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO Investor Forum Company Snapshot: Syntrix Biosystems

SyntrixBioLogo_3D

1.     What is your company’s lead product or technology? Omnitram (O-desmethyltramadol) is a novel  oral analgesic developed by Syntrix that alleviates pain via a dual mechanism involving mu-opioid receptor activation and inhibition of the reuptake of norepinephrine.  Omnitram is in clinical development and has just completed a Phase 1b double-blind, placebo-controlled clinical trial (N=40) in experimental pain. 2.     What sets your company apart from competitors? Omnitram is a proprietary solution for pain relief that is Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , ,